ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2328

Increased Risk of Stroke In Patients With Psoriasis: A Systematic Review And Meta-Analysis
Abstract Number: 2329

Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
Abstract Number: 2330

Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study
Abstract Number: 2331

Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Abstract Number: 2332

Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Abstract Number: 2333

Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
Abstract Number: 2334

Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
Abstract Number: 2335

The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
Abstract Number: 2336

Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry
Abstract Number: 2337

A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
Abstract Number: 2338

Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Abstract Number: 2339

Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
Abstract Number: 2340

Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Abstract Number: 2341

Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Abstract Number: 2342

Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].